Davita Inc vs United Microelectronics Corp — how do they compare? Davita Inc trades at $227.08 (market cap $14.92B), while United Microelectronics Corp trades at $25.02 (market cap $59.23B). The key difference: United Microelectronics Corp is far larger — about 4× Davita Inc's market cap, and United Microelectronics Corp pays a 1.73% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | UMC | |
|---|---|---|
Market Cap | $14.92B | $59.23B |
Sector | Health | Technology |
52-Week High | $235.71 | $28.02 |
52-Week Low | $103.87 | $6.58 |
Enterprise Value | $27.47B | $56.81B |
Dividend Yield | — | 1.73% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
UMC trades at $23.46, down 3.62% over the past day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.20, exceeding expectations of $0.12, and announced a $0.41 dividend payable in August 2026. Revenue grew to $237.55 billion in 2025, though net income margin has declined from 32.1% in 2022 to 16.99% in 2025. Positive developments include mass production of silicon photonics ICs and a new 14nm eHV FinFET platform.
Outlook remains mixed with strong operational cash flow and technological advancements balanced against high valuation multiples and margin compression. Key risks include competitive pressures in semiconductor foundry markets and sensitivity to global economic cycles. Analyst consensus is cautious with 53.3% hold ratings, suggesting limited near-term upside despite solid fundamentals.
Trailing returns across standard periods
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →